In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
List view / Grid view
Filter the results
Scientists reveal eight new molecules, five of which are already US FDA-approved, that can block the polymerase reaction SARS-CoV-2 uses to replicate its genome.
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
Researchers have identified differences in gene transcription within key immune cells that may distinguish those individuals infected with HCV...
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
17 May 2016 | By Katie Sadler
Virologists have discovered that an antiviral drug against hepatitis C has helped slow down the development of Zika virus in Mice.
14 December 2015 | By Victoria White
Their research identified eight complete strains of human pegivirus 2, which makes it the first study to reveal the entire genetic makeup of this new virus...
VBI Vaccines presents data supporting the use of its eVLP platform to develop a novel HCV vaccine candidate
4 June 2015 | By Victoria White
VBI Vaccines has delivered a presentation that supports the potential use of its eVLP platform in the development of a novel Hepatitis C vaccine candidate...
22 May 2015 | By Victoria White
Achillion and Janssen have entered into a worldwide license and collaboration arrangement to develop and commercialise one or more of Achillion's HCV assets...
Partnering for Cure programme announces new winning projects designed to investigate novel ways to cure viral diseases
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR12 rates of up to 90%
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
New data from Phase 3 attain study of Janssen’s once-daily simeprevir compared to telaprevir in treatment-experienced adult patients with genotype 1 chronic hepatitis C
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...